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ABSRACT Progressive loss of the telomeric ends of chromosomes caused by the semi-conservative mechanism of 
DNA replication is an important timing mechanism which controls the number of cells doubling. Telomerase is 
an enzyme which elongates one chain of the telomeric DNA and compensates for its shortening during replica-
tion. Therefore, telomerase activity serves as a proliferation marker. Telomerase activity is not detected in most 
somatic cells, with the exception of embryonic tissues, stem cells, and reproductive organs. In most tumor cells 
(80–90%), telomerase is activated and plays the role of the main instrument that supports the telomere length, 
which can be used for the diagnostics of neoplastic transformation. This is the primary reason why assays re-
garding the development of telomerase activity have attracted the attention of researchers. Telomerase activity 
testing may be useful in the search for telomerase inhibitors, which have the potential to be anti-cancer drugs. 
Moreover, telomerase activation may play a positive role in tissue regeneration; e.g., after partial removal of the 
liver or cardiac infarction. 
All telomerase activity detection assays can be divided into two large groups: those based on direct detection of 
telomerase products, and those based on different systems of amplification of the signals from DNA that yield 
from telomerase. The methods discussed in this review are suitable for testing telomerase activity in different 
samples: in protozoa and mammalian cells, mixed cellular populations, and tissues. 
KEYWORDS telomerase, telomerase activity assay, tumor diagnostics, physicochemical methods, polymerase ac-
tivity assay, DNA determination.
WHAT IS TELOMERASE AND WHY DO WE 
NEED TO DETERMINE ITS ACTIVITY? 
In 1961, Hayflick and Moorhead demonstrated that a 
somatic cell culture has a limited life period (the Hay-
flick limit) [1]. In 1973, Olovnikov postulated that the 
number of cell divisions can be determined by the 
shortening of the telomeric ends of chromosomes [2], 
which play the role of a timing mechanism in cells. Te-
lomeres protect the cell genome against degradation 
and participate in the meiotic pairing of chromosomes 
and the regulation of the transcription of the genes lo-
cated in the pretelomeric region [3, 4]. Present in im-
mortalized cells (with the ability of infinite division) is a 
mechanism that compensates for telomere shortening. 
In 1985, Blackburn and Greider discovered telomerase, 
an enzyme that elongates one of the telomere chains 
[5].
Telomerase is an RNA–protein complex; its main 
components are an RNA-matrix for telomere synthesis 
(TERC), which also has a structural function, and re-
verse transcriptase (TERT) [6]. The telomerase complex 
(telomerase) binds with a telomere or an oligonucle-
otide, the sequence of which may differ from the tel-
omere sequence (telomere-imitating oligonucleotide), 
and synthesizes a short DNA fragment (in mammals, 
GTTAGG). Next, telomerase moves to the telomeric 
end (translocation) and again synthesizes a DNA frag-
ment (Fig. 1). Telomerase activity is proportional to 
the total amount of DNA that it synthesizes, while the 
processivity is in proportion to the length of the frag-
ments synthesized.
Telomerase activity is a marker of the proliferative 
activity of cells. Telomerase components may perform 
functions that are independent of the arrangement 
of the active complex. For example, hTERT (human 
TERT), regardless of the presence of hTERC (human 
TERC), may function as an RNA-dependent RNA-poli-
merase [7]. An enhancement of hTERC expression does 
not necessarily coincide with the emergence of telom-
erase activity [8]. hTERC inhibits protein kinase ATR, 
the targets of which are the known tumor growth sup-
pressor p53 and CHK1 protein kinase at a checkpoint 
control, which is part of the system of signal transmis-
sion from the damaged DNA. A decrease in the hTERC 
level leads to stoppage of the cell cycle at G1 and G2 
phases as a result of the activation of the p53 protein 
and CHK1 protein kinase. However, the mechanism of 
this activity has yet to be revealed [9].
Telomerase activity has not been detected in the vast 
majority of normal human cells; however, it manifests 
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itself in reproductive organs and embryonal tissues. 
Thus, the enzyme is active in stem cells and some rap-
idly regenerating tissues, such as the intestinal epitheli-
um; however, in this case telomerase activity is usually 
lower than it is in tumor cells (Fig. 2). Telomerase activ-
ity is more typical of malignant tumors, its activity and 
detection frequency being noticeably lower in benign 
tumors [10]. Detection of telomerase activity is used for 
both tumor diagnostics and in the search for potential 
anti-tumor drugs that would act as telomerase inhibi-
tors. Furthermore, telomerase participates in tissue 
regeneration after the partial removal of the liver or 
cardiac infarction. In addition, the role of telomerase in 
the ageing process, in connection with the telomere’s 
function as a cell-timing mechanism, attracts a signifi-
cant degree of interest.
METHODS COMPRISING THE AMPLIFICATION 
OF TELOMERASE-SYNTHESIZED DNA (TRAP)
The most common methods for detecting telomerase 
activity are TRAPs (telomeric repeat amplification pro-
tocols) [11], which allow one to perform semi-quanti-
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Fig. 2. Dependence of telomere 
length on the number of cell 
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tative and quantitative analyses, using some of their 
modifications. Such modifications include: increase of 
the analysis rate, replacement of the radioactive label 
by nonlabeled compounds, the reduction of the amount 
of side products, etc. Among these methods are the 
scintillation proximity assay, hybridization protection 
assay, transcription amplification assay, and the mag-
netic bead-based extraction assay [12]. Some modifica-
tions even enable to detect telomerase activity within a 
single cell [13]. 
The telomeric repeat amplification protocol can be 
subdivided into three main stages: primer elongation, 
amplification of telomerase-synthesized DNA, and 
thirdly, its detection. At the elongation stage, telom-
eric repeats are added to the telomere-imitating oligo-
nucleotide (TS, Table 1) by telomerase present in the 
cell extract. Then, PCR-amplification of telomerase-
synthesized DNA is carried out with the use of specific 
primers (telomere-imitating and reverse primers). At 
this stage, different labels can be incorporated into the 
telomerase-synthesized DNA, such as radioactive, fluo-
rescent, or affine labels. This stage is then followed by 
detection (in the original method, it comprises electro-
phoretic separation of PCR products and photograph-
ing) (Fig. 3).
The original TRAP method has several drawbacks. 
Initially, the CX oligonucleotide, which complemen-
tarily overlaps with TS for several bp, is used in the 
amplification of PCR products. It results in the dimeri-
zation of primers and products that emerge due to the 
interaction between primers. Even when using the op-
timal ACX primer with the noncomplementary TS end, 
a background signal may emerge during the analysis 
of concentrated extracts from tumor tissues [14]. An 
additional problem is encountered when using reverse 
primers which completely correspond to telomeric re-
peats. The primers are not annealed at the matrix edges 
during PCR (as a result of periodicity in telomeres), and 
hence false signals emerge. This problem is typically 
solved by adding regions that are noncomplementary to 
telomeres (Table 1) with a 5’-end nontelomeric “appen-
dix” made of 6 bp to the primer ends. In order to reduce 
Table 1. Some oligonucleotides that are used in different 
TRAP modifications
Oligo-
nucleo  tide 
name
Oligonucleotide sequence
TS 5’-AATCCGTCGAGCAGAGTT-3’
CX 5’-(CCCTTA)3CCCTAA-3’
ACX 5’-GCGCGG(CTTACC)3CTAACC-3’
RP 5’-TAGAGCACAGCCTGTCCGTG-3’
RPC3 5’-TAGAGCACAGCCTGTCCGTG(CTAACC)3-3’
TSG4 5’-GGGATTGGGATTGGGATTGGGTT-3’
1. Elongation of the telomere-imitating 
primer by telomerase
2. Amplification  
of telomerase products
3. Separation of the products in polyacrylamide gel and detection
TS
TS +6, +12, +18 ...   5’
5’
5’
5’
5’
5’
3’
3’
3’
3’
3’
ACX
Fig. 3. Telomeric 
repeat amplifica-
tion protocol 
(TRAP).REVIEWS
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nonspecific signals, it is possible to use a combination of 
several primers that are used as reversed ones (more 
information on the two-primer system is given below, 
primers RP and RPC3 are given in Table 1). Oligonu-
cleotide TSG4 (Table 1) can also be added to the TRAP 
mixture in order to assess the effect of duplex-stabi-
lizing inhibitors; this oligonucleotide does not require 
the synthesis of several repeats by telomerase before 
the inhibitor begins its action [15]. The advantages and 
drawbacks of the various nucleotides used in TRAP 
were discussed more thoroughly in [12]. Moreover, in 
the case when PCR is used for signal amplification, the 
PCR inhibitors contained in the specimen can impact   
the results of telomerase activity detection.
Originally, in the TRAP method, PCR products 
were detected in polyacrylamide gel (PAAG) on ac-
count of the radioactive label, which was introduced 
using a radioactively labeled primer or incorporated 
into the DNA during the reaction. The method allows 
to perform a qualitative assessment of the activity and 
processivity of telomerase in cell and tissue extracts; 
however, as previously stated this requires radioactive 
specimens.
PCR at the second stage of TRAP allows to obtain an 
amount of DNA sufficient for gel staining, e.g., using 
ethidium bromide [16] (an appreciably strong mutagen 
with a low sensitivity), silver nitrite [17] (its sensitiv-
ity is equal to that when using the radioactive label; 
however, the method is more laborious and relatively 
expensive), and Sybr Green [18] and its analogs (its sen-
sitivity is equal to that when using the radioactive label 
[19], while mutagenicity is considerably higher than 
that in ethidium bromide, although it is an intercalating 
dye, as well).  Fluorescent labeling of the nucleotides 
employed in TRAP can also be used [20].
Purification of telomerase-synthesized DNA and 
TRAP efficiency
It is appreciably simple to obtain extracts of tumor cells 
or cell lines and detect telomerase activity in them, 
even though the tissues are composed of several cell 
types and may contain compounds that have an effect 
on the quantitative and even qualitative assessment of 
telomerase activity. Therefore, false-positive or false-
negative results can be obtained, and they may affect 
the validity of the diagnosis and prognosis of a dis -
ease. The features of biopsic specimens, such as large 
volumes of fluid (blood, etc.) or presence of numerous 
normal cells, may complicate the detection of telom-
erase activity, as well. In these cases, the extraction of 
telomerase-synthesized DNA can be carried out using 
modified magnetic beads. During this procedure, PCR 
inhibitors are removed or strongly diluted. The TRAP 
method involving this extraction consists of three main 
stages: the elongation of the substrate-imitating oligo-
nucleotide by telomerase, the extraction of telomerase-
synthesized DNA using modified magnetic beads, and 
amplification. 
During the extraction stage, telomerase-synthesized 
DNA is hybridized with the C-rich biotin-conjugat-
ed primer (CCCTAA)2 and isolated from the extrac-
tion mixture using the magnetic beads coated with 
streptavidin-coated magnetic beads. Then, the telom-
erase-synthesized DNA is released from the complex 
by heating, and PCR is carried out. The sensitivity of 
this modification towards PCR inhibitors is lower by 
an order of magnitude as compared with the standard 
TRAP method; its efficiency is slightly higher during 
the analysis of tissue and other complex specimens 
[21]. Phenol-chloroform extraction can be used instead 
of the biotin-conjugated primer and magnetic beads 
[16], although in this case it becomes more difficult to 
remove the impurities that are more soluble in water 
than in organic solvents.
Internal standards for TRAP
Internal standards (amplified with the same primers as 
telomerase-synthesized DNA) allow for the presence of 
Taq polymerase inhibitors (e.g., gem-containing com-
pounds) in the specimens to be taken into consideration, 
and for the performing of the total control of PCR. They 
can also be used for the standardization of the amount 
of telomerase-synthesized DNA. There are two most 
common standards, with the length of 36 and 150 bp. 
The 36 bp standard is excessively amplified if the spec-
imens have a low telomerase activity, competes with 
the telomerase-synthesized DNA, and provides a false-
negative signal [18]. The 150 bp standard is more sen-
sitive towards the Taq polymerase inhibitors present 
in the reaction mixture. The standards can be used in 
TRAP with real-time PCR and primers in which the 
fluorescent label differs from that in primers for the 
amplification of telomerase-synthesized DNA [22].
TRAP with an additional specific reverse primer 
(“two-primer” TRAP)
Two-primer TRAP is a modification of the standard 
TRAP which is used to reduce false signals (Fig. 4). 
In this TRAP version, no electrophoretic analysis of 
PCR products is carried out. Instead, the total radioac-
tivity is assessed as a criterion of telomerase activity. 
The telomerase-synthesized DNA is amplified using 
two reverse primers with lengths of 20 (RP) and 38 
(RPC3) nucleotides (Table 1), in the presence of [3H]TTP 
or [α-32P]dСTP; the amount of the longer primer added 
is 50 times lower than that of the shorter primer. After 
the PCR, the two-chain DNA is isolated by deposition 
and filtration. The advantage of this method is that, 52 | ACTA NATURAE |  VOL. 3  № 1 (8)  2011
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due to the low concentration of the RPC3 primer, the 
amount of products of interaction between the primers 
is reduced, while the presence of standard amounts of 
the RP primer ensures a significant degree of amplifi-
cation of the telomerase-synthesized DNA [23, 24]. This 
method makes it possible to qualitatively determine te-
lomerase activity in extracts of tissues and cell lines. 
The sensitivity threshold of this method is the 10-cell 
extract of the telomerase-positive cell line.
TRAP with fluorescence resonance energy transfer 
(FRET)
One of the alternatives to DNA staining in the TRAP 
method is to use primers with energy transfer (amplif-
luors). Amplifluors are characterized by their unique 
hairpin structure, which contains a donor (fluorescein) 
and acceptor (4’-dimethylaminophenyl-azobenzoic 
acid). Fluorescence manifests itself only in the case 
when a primer incorporates into PCR products; i.e., the 
necessity for using radioisotopes disappears, and the 
volume of post-PCR analysis considerably decreases. 
The replacement of the telomerase substrate and re-
verse primer by amplifluors allows to achieve an in-
creasingly high intensity of the fluorescent signal. The 
primers that are used for amplification of the internal 
standards need to have a donor-acceptor pair with a 
fluorescence wavelength that differs from that of the 
primers used for amplification of telomerase-synthe-
sized DNA [22].
The method involving the use of the time-resolution 
fluorescence resonance energy transfer (HTRF) com-
bines the standard FRET technique and a long-lived flu- long-lived flu-
orescent donor. The method is based on the use of euro- The method is based on the use of euro-
pium or terbium cryptate complexes. These lanthanides 
are characterized by a long fluorescence decay period, 
whereas the complexation of macrocyclic compounds 
yielding cryptate complexes additionally enhances their 
stability [25]. A deoxyuridin triphosphate labeled with 
europium cryptate was used to assess the amount of 
DNA in TRAP with biotin-conjugated oligonucleotide 
TS. After the allophycocyanin–streptavidin, a conjugate 
was added and the FRET signal of DNA in TRAP was 
observed [26] (Fig. 5). This method allows a semi-quan-
titative detection of telomerase activity in tissue and cell 
line extracts. The sensitivity threshold of this method is 
the 10-cell extract of the telomerase-positive cell line.
TRAP with detection using the scintillation proximity 
assay
Another means for the detection of the DNA amplified 
in TRAP without PAAG is the scintillation proximity 
assay. When used in combination with the traditional 
MTS primer
MTS primer
1. Elongation of MTS primer by telomerase
2. Binding of reverse RPC3 primer in the first two 
cycles
RPC3 primer
RPC3 primer
3. DNA synthesis in the first two cycles
4. Binding of RP primer in cycles 3–29
RP primer
5. DNA synthesis in cycles 3–29
Fig. 4. “Two-primer” TRAP scheme [23, 24].
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Fig. 5. Scheme of the TRAP method with time-resolution 
fluorescence energy resonance transfer [26]. F – fluoro-
phore, a – avidin, b –biotin, and K – analog of deoxyurid-
intriphosphate labeled with europium kryptate.REVIEWS
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TRAP, it helps increase the rate of detection of telom-
erase activity. 5’-Biotin-conjugated oligonucleotides act 
as substrates in this method; the amplification takes 
place in the presence of [3H]TTP. Biotin-conjugated 3H-
labeled DNA binds with streptavidin-coated fluoromi-
crospheres, which contain a scintillator that emits in the 
presence of tritium (Fig. 6). Thus, instead of separating 
DNA in a gel followed by photo-detection, the yield 
of PCR products is assessed on a scintillation counter, 
which allows to reduce the assay time after the PCR 
to 1 h and semi-quantitatively determine telomerase 
activity in large series of tissue and cell line extracts. 
The sensitivity threshold of this method is the 10-cell 
extract of the telomerase-positive cell line. The major 
drawback of this method is the use of tritium. Further-
more, like most methods for detecting TRAP products 
without PAAG, it is sensitive to PCR artifacts [27].
TRAP with detection using the hybridization protec-
tion assay
TRAP modification in which the hybridization pro-
tection assay (Hybridization protection assay-TRAP) 
is used is a safer modification. Probes labeled with 
covalently bound acridine [28] are used in this meth-
od for detecting DNA after the amplification (Fig. 7). 
The same detection scheme is used in the transcrip-
tion scheme of telomerase repeat amplification. This 
method allows for semi-quantitative determination of 
telomerase activity in tissue and cell line extracts. The 
sensitivity threshold of this method is the 10-cell ex-
tract of the telomerase-positive cell line.
TRAP combined with enzyme-linked immunosorbent 
assay (ELISA)
In the TRAP-ELISA method, DNA after the amplifi-
cation is determined colorimetrically, facilitating the 
qualitative and semi-quantitative assessment of tel-
omerase activity. Biotin-conjugation of the TS primer 
allows for the binding of the amplified DNA to strepta-
vidin-coated microplates (Fig. 8). The amplified DNA 
denatures and is hybridized with digoxigenin (DIG)-
labeled probes, which demonstrate specificity towards 
telomeric repeats, and binds to the microplates due to 
the streptavidin–biotin interaction. This complex can 
Amplified biotin-
conjugated telomerase 
products labeled with 
3H
Streptavidin-coated 
fluoromicrospheres that 
contain a scintillator emit-
ting in the presence of 
tritium
Binding
Detection of radiation on the scintillator
Fig. 6. Scheme for TRAP with scintillation proximity assay.
Amplified telomerase 
products Acridine-labeled 
probe
Probe binding
Photodetection
Fig. 7. Scheme for TRAP with hybridization protection 
assay.
Biotin-conjugated reaction 
products
Dioxigenin-labeled  
probe
DIG
DIG
DIG DIG
DIG DIG
DIG-antibod-
ies–enzyme 
conjugate
Binding of the DIG-anti-
bodies–enzyme conjugate
Binding with streptavidin-coated  
microplates for titration
Binding of the dioxigenin-labeled probe
Fig. 8. Scheme for ELISA detection of PCR products in 
TRAP-ELISA (or detection of telomerase reaction prod-
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be detected using polyclonal sheep antibodies to DIG 
conjugated to horseradish peroxidase; the activity of 
the latter is determined colorimetrically [29, 30]. This 
method differs from the hybridization version by the 
emergence of a second step of signal amplification due 
to the enzymatic reaction.
One of the drawbacks of the TRAP-ELISA method 
is the complexity in separating the telomerase-positive 
and telomerase-negative controls, which may result 
from the absence of internal controls and two steps of 
signal amplification. Nevertheless, the TRAP-ELISA 
method is faster as compared with TRAP, which is 
based on the separation of the amplified DNA in gel. 
This fact makes it possible to use the TRAP-ELISA 
method in screening studies. The method is suitable for 
semi-quantitative determination of telomerase activity 
in tissue and cell line extracts. The sensitivity threshold 
of this method is the 10-cell extract of the telomerase-
positive cell line.
 
TRAP with electrochemical detection
After the PCR, the nonreacted nucleotide triphos-
phates can be separated, followed by treatment of the 
remaining products with 3 M HCl. In the method under 
consideration, dGMP, one of the products of the com-
plete hydrolysis of the amplified DNA, is determined 
electro-chemically [31]. The method makes it possible 
to semi-quantitatively determine telomerase activity 
in tissue and cell line extracts. The sensitivity threshold 
of this method is the 10-cell extract of the telomerase-
positive cell line. The method has no special advantages 
over other methods in which no gel-electrophoresis or 
radioactive labeling are used. However, the method is 
more laborious.
TRAP with real-time PCR
Real-time PCR is used for simultaneous DNA am -
plification and measurement of the amount of prod-
ucts obtained after each amplification cycle. Standard 
TRAP, combined with real-time PCR, allows to obtain 
quantitative results [32, 33]. This method is suitable 
for studying telomerase inhibitors and analyzing large 
specimen series [12]. When comparing it with the con-
ventional TRAP, it can be noted that over-estimation 
of telomerase activity and leveling of small differences 
in the activity is possible without the assessment of the 
amount of real-time PCR products, due to saturation 
of the PCR reaction in the final stages. Moreover, the 
possibility of dimerization of primers resulting in the 
emergence of a false-positive signal causes an addi-
tional problem. This problem can be made more acute 
when using the reverse anchor-primer, which will im-
pede dimerization, reduce the number of primers and 
number of cycles, resulting in dimerization of primers 
to occur mostly at late stages of the program (35–39 cy-
cles); in the meantime, the number of cycles is 28 in the 
standard TRAP. This problem is also mitigated when 
measuring fluorescence in the early exponential phase 
of PCR [32]. The method makes it possible to quantita-
tively determine telomerase activity in tissue and cell 
line extracts. The sensitivity threshold of this method 
is 10 to 50 cell extracts of the telomerase-positive cell 
line.
Similar to the standard TRAP with gel-electrophore-
sis, TRAP with real-time PCR has several variants of 
detection, e.g., using the probes which are specific to 
the telomerase-synthesized DNA amplified in the PCR 
and fluoresce only as a component of a duplex. Other-
wise, these probes will form the nonfluorescent hairpin 
structure [34]. The advantages of this method include a 
high rate of detection of telomerase-synthesized DNA 
upon flow analysis and enhanced specificity due to the 
use of corresponding probes [35]. The method allows 
semi-quantitative determination of telomerase activity 
in tissue and cell line extracts. The sensitivity threshold 
of this method is the 10-cell extract of the telomerase-
positive cell line.
TRAP on microchips
TRAP on microchips is the combination of the two-
primer TRAP and binding of PCR products on chips, 
followed by probe hybridization and detection. Various 
fluorescent labels are used to determine telomerase-
synthesized DNA and the internal standard; e.g., Cy3 
for the telomerase-synthesized DNA being amplified 
and Cy5, for the standard.
In situ TRAP
Telomerase activity is typically analyzed in a cell ex-
tract. If cell lines are homogeneous, the result repre-
sents the telomerase activity in cells. When the extracts 
of tumor tissue specimens are investigated, it is rea-
sonable to consider only the mere fact of the presence 
or absence of telomerase activity, since the content of 
tumor cells in such specimens varies from 3 to 90% and 
more. In this case, the results obtained reveal nothing 
about the level of telomerase activity in various types 
of cells constituting the tissue or on the differences be-
tween tumor and normal cells within the same tissue 
(e.g., an increase in telomerase activity in blood is as-
sociated with the emergence of activated leukocytes 
or degeneration of certain blood cells). In order to over-
come this drawback, the in situ TRAP method was de-
signed, in which FITC-labeled direct and reverse prim-
ers are used [36]. In this method, the cell suspension 
specimens are immobilized onto silane-coated glasses 
and dried with cold air. The reaction mixture for TRAP REVIEWS
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is then applied onto each specimen, followed by incuba-
tion. Telomerase is inactivated via heating, the reverse 
primer with polymerase is added, and in situ PCR is 
performed. Upon completion of the reaction, the glasses 
are analyzed on a fluorescence microscope; cell types 
are identified by the staining procedure. The fluores-
cence intensity and its localization (nucleus/cytoplasm) 
are used to determine telomerase activity in separate 
cell types within the mixture. High telomerase activ-
ity in urogenital and bronchial lavages manifests itself 
through bright fluorescence of the nuclei of malignant 
(but not benign) cells [37, 38]. A comparison with the 
conventionally stained specimens points to association 
between the fluorescence in the nucleus with malignant 
cells, whereas the signal from cytoplasm is detected in 
granulocytes and macrophages [39]. A similar correla-
tion was found during the analysis of pleural effusion 
[40]. Moreover, in situ TRAP has been successfully used 
not only for the cell suspension specimens, but also on 
tissue sections (in particular, for diagnostics of liver 
cancer) [41]. The method allows for a semi-quantitative 
determination of telomerase activity and its localization 
in isolated cells of tissues and cell suspensions.
Transcription amplification of telomerase-synthesized 
DNA
In order to increase the amount of telomerase-syn-
thesized DNA, PCR is replaced by transcription am-
plification. Combined with “hybridization protection,” 
this method allows to determine the telomerase activ-
ity as quickly as after 4 hours. The primer, which acts 
as a substrate for telomerase, contains the site of T7-
RNA-polymerase binding, along with the telomere-
imitating sequence. The telomerase-synthesized DNA 
acts as a substrate for hybridization of the reverse 
primer, which contains an additional sequence that is 
noncomplementary to the telomeric repeats. Due to 
this sequence, the reverse primer binds with the end 
of the telomerase-synthesized DNA, and the comple-
tion of the double-chain DNA takes place at the next 
RNA
RNA
RNA
DNA
DNA
DNA
DNA
DNA
DNA
DNA
DNA
T7-RNA-
polymerase 
promoter
Telomerase  
substrate
Synthesis by DNA polymerase
Annealing of reverse primer
Elongation of the reverse primer by reverse transcriptase
Reverse primer
Synthesis by RNA polymerase
Annealing and removal of reverse primer
Destruction of RNA by RNAse and annealing of direct primer
Elongation of direct primer by reverse transcriptase
Synthesis by RNA polymeraseAnnealing of reverse primer
Fig. 9. Scheme of 
telomerase activity 
detection with the 
PCR amplification of 
telomerase prod-
ucts for transcrip-
tional amplification 
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stage. T7-RNA-polymerase uses this DNA as a matrix 
to synthesize RNA. This RNA is used by the reverse 
transcriptase to synthesize a new DNA chain. RNA is 
then removed by RNase; the second DNA chain of the 
single-chain DNA is completed with the aid of the di-
rect primer (Fig. 9).
Using this scheme, telomerase-synthesized DNA can 
be amplified at 40oС for 75 min in amounts comparable 
with PCR. The subsequent reactions may be carried out 
in the same tube as those in which amplification takes 
place. The method’s sensitivity allows to detect telom-
erase activity in specimens consisting of 1–1,000 cells. 
The method is sensitive towards the presence of RNas-
es [12, 42]. The major advantage of this method over 
TRAP with PCR amplification is that no heating of a 
specimen is required upon amplification and that the 
specific Taq polymerase inhibitors are neglected. This 
method makes it possible to semi-quantitatively de-
termine the telomerase activity in tissue and cell line 
extracts. The sensitivity threshold of this method is the 
10-cell extract of a telomerase-positive cell line.
DIRECT DETECTION OF TELOMERASE-SYNTHESIZED DNA
Detection of telomerase activity using direct incorpo-
ration of a radioactively labeled substrate
The method is based on the ability of telomerase to 
elongate oligonucleotides in the presence of dNTP. If an 
oligonucleotide or one of the dNTP (typically, dGTPl, 
since telomerase-synthesized telomeres are enriched 
in guanine residues) contains a radioactive label, tel-
omerase activity can be electrophoretically assessed by 
its incorporation into DNA [43]. The major drawbacks 
of this method include the use of large amounts of ra-
dioactive isotopes and insufficient sensitivity (in many 
cases), which is conditioned by a low telomerase con-
tent in cells and tissues.
The first method used for telomerase activity detec-
tion was a method in which radioactive labeling was 
used without any additional amplification. This method 
is still employed today for the thorough investigation of 
telomerase-synthesized DNA and quantitative meas-
urements. The method allows for qualitative determi-
nation of the activity and processivity of telomerase 
in cell line extracts; however, it is characterized by 
low sensitivity (10,000 cells of telomerase-positive cell 
line).
Determination of telomerase-synthesized DNA by 
changes in surface plasmon resonance
Surface plasmon resonance (SPR) manifests on a met-
al’s surface under conditions of total internal reflection 
and is characterized by a nonspecific angle of reflec-
tion and, therefore, the refraction index. As this effect 
manifests itself on the surface of a metal film, it propa-
gates deep into the solution with exponential damping 
as a distance function. The interactions between the 
molecules change the damped wave, which has an ef-
fect on the characteristics of the surface plasmon and 
manifests itself in the variation of the resonance angle 
and the refraction index in the near-surface layer. The 
interaction between bio-molecules is judged by the al-
teration of the refraction index (Fig. 10A).
SPR can be used to determine telomerase activity as 
the corresponding elongation of a telomere-imitating 
oligonucleotide, using a biosensor.
5’-Biotin-conjugated oligonucleotides, which con-
tain telomeric repeats, are in situ immobilized on the 
surface of a dextrane sensor pretreated with streptavi-
din on a BIACORE instrument. They are then treated 
with a cell extract. If the extract contains telomerase, 
binding of telomerase takes place and the oligonucle-
otide is elongated, which is determined by SPR after 
proteins are removed with a sodium dodecyl sulfate 
solution (Fig. 10B). The degree of oligonucleotide elon-
gation depends on specimen concentration and reac-
tion time. The results of the analysis of tumor and cell 
line extracts using this method, as well as the results of 
testing telomerase inhibitors, correlate with the data 
obtained by the TRAP method [44]. The signal intensity 
can be increased by treating the sensor with telomer-
ase-synthesized DNA with antisense oligonucleotides 
with respect to the telomeres that are covalently bound 
with streptavidin and gold nanoparticles [45].
This method allows to quantitatively determine tel-
omerase activity in tissue and cell line extracts and col-
lect data on the kinetics of the reaction, demonstrat-
ing the binding and dissociation of telomerase from the 
substrate. The sensitivity threshold of this method is 
the 50-cell extract of the telomerase-positive cell line.
Determination of telomerase activity using oligo-
modified magnetic particles and NMR
This method is based on the use of magnetic particles 
of an iron oxide which are modified with oligonucle-
otides that are complementary to telomeric repeats. 
These particles bind to the telomerase-synthesized re-
peats due to complementary interactions and form ex-
tended linear structures (MRS complexes) (Fig. 11A). 
The effect of this hybridization is determined by the 
spin-spin relaxation time. During the formation of an 
organized nanoparticle ensemble, there is a noticeable 
change in the magnetic relaxation time of the sur -
rounding water molecules, which can be measured 
in a relaxometer (the relaxometer measures both the 
spin-spin relaxation times of the nuclear magnetiza-
tion of proton-bearing liquids in multi-component 
systems and the content of components with different REVIEWS
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relaxation times). The magnetic switching occurs rap-
idly, attaining half of the maximum change after 30s 
and reaching a plateau after 40–60 min (Fig. 11B). The 
magnetic switching has been confirmed by magnetic 
force microscopy and by correlation of the magnetic 
switching and the size of the nanoensembles being 
formed. The local distortion of the magnetic field in-
creases on nanoparticles in ordered ensembles, where-
as the nonordered nanoparticles provide a consider-
ably lower magnetic effect [46].
The relaxation time was measured in a volume of 
200–500 µl in an NMR spectrometer at a magnetic in-
duction of 0.47 T. For the magnetic resonance scanning 
of 384 well plates with 50 µl of the mixture at 1.5 T, the 
spin-spin relaxation (T2) and spin-lattice relaxation (T1) 
times were assessed. The adaptation to the flow treat-
ment using magnetic resonance scanning made it possi-
ble to analyze several hundred specimens as quickly as 
in several tens of minutes with high sensitivity [46]. The 
method allows for the quantitative determination of 
telomerase activity in tissue and cell line extracts using 
the high-performance microplate format. In addition to 
the common instruments and reagents, these analyses 
require a plate NMR-spectrometer and a specimen of 
oligonucleotide-modified nanoparticles. The sensitiv-
ity threshold of this method is the 10-cell extract of the 
telomerase-positive cell line. 
Determination of telomerase activity using the quartz 
crystal microbalance technique
An Au-quartz resonator can be used for a microgravi-
tometrical analysis of telomerase activity, according 
to the quartz crystal microbalance technique. Quartz 
crystals possess a piezoelectric effect. Alternation of the 
current imposition results in the emergence of oscilla-
tions in a quartz crystal; in specially curved crystals, 
a current of a certain frequency may lead to the for-
mation of a stationary wave. Its resonance frequency 
can be quite accurately determined. The wave changes 
upon ligand binding on the crystal’s surface. The quartz 
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crystal microbalance technique in liquids is utilized to 
determine the affine binding of molecules (in particu-
lar, proteins) on surfaces that contain the correspond-
ing recognition sites.
In this method, the telomere-imitating oligonucle-
otide is bound to the sensor’s surface, elongated by te-
lomerase. Next, the synthesized DNA chain is hybrid-
ized with a biotin-conjugated oligonucleotide (Fig. 12A). 
An alternative variant includes the elongation of the 
telomere-imitating oligonucleotide that is bound to 
the sensor in the presence of a biotin-labeled NTP 
(Fig. 12B). Next, the sensor’s surface is treated with an 
avidin–alkaline phosphatase conjugate and a solution 
of alkaline phosphatase substrate – 5-bromo-4-chloro-
3-indolylphosphate, which upon hydrolysis yields an 
insoluble product on the sensor’s surface. When deter-
mining telomerase activity through a decrease in the 
resonance frequency of the crystal, it is possible to ob-
serve the steps of oligonucleotide elongation, binding 
with the telomerase-synthesized DNA of the avidin–
alkaline phosphatase conjugate, and the deposition of 
products of the reaction catalyzed by the alkaline phos-
phatase on the crystal’s surface [47]. The method allows 
for the quantitative determination of the telomerase 
activity in tissue and cell line extracts. The sensitivity 
threshold of this method is the 3,300-cell extracts of the 
telomerase-positive cell line at a high rate. A frequency 
analyzer and an Au-quartz crystal are needed in this 
method. Moreover, the identification of artifact signals 
is complicated.
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Electrochemical detection of telomerase activity with 
ferrocenyl naphthalene diimide
This method is based on the ability of telomeric repeats 
to form G-quadruplexes. Telomerase elongates an oli-
gonucleotide that is immobilized on an electrode. The 
synthesized telomeric then repeats when there is a high 
concentration of potassium ions, forming quadruplexes; 
while ferrocenyl naphthalene diimide can stoichiomet-
rically bind with DNA quadruplexes under these con-
ditions and stabilize their structure (Fig. 13). In turn, 
the bound ferrocenyl naphthalene diimide can be de-
tected using electrochemical methods. In this method, 
the quantities of DNA fragments that are folded into a 
quadruplex are assessed. This number depends not only 
on the total number of repeats, but also, to an unpre-
dictable degree, on the length and position of individual 
DNA fragments, which can be considered a drawback. 
The sensitivity of the method is sufficient to detect 
the telomerase-synthesized DNA without amplifica-
tion [48] (100–1,000 cells of the telomerase-positive cell 
line); however, this method has not as yet been tested 
on a tumor tissue extract.
Biobarcode assay for telomerase activity detection
Today, the most sensitive method for direct detection 
of telomerase activity without amplification of the 
telomerase-synthesized DNA is based on the biobar-
code system. In the original biobarcode system, mag-
netic particles bind to a target, which in turn binds 
to nanoparticles covalently modified with an oligonu-
cleotide due to antigen-antibody interactions. These 
nanoparticles serve as a biological barcode. The result-
ing “sandwich” is isolated from the reaction mixture 
in the magnetic field and denatured; the result is de-
termined by the released DNA fragments. In the sys-
tem of telomerase activity detection, the telomerase-
synthesized DNA is recognized using complementary 
DNA fragments. DNA nanoparticles consist of gold 
nanoparticles and oligonucleotides of two types; one 
of these can form a duplex with the telomerase-syn-
thesized DNA, whereas the second cannot. Because 
of this, the probability of binding another DNA-tar-
get to the same nanoparticle is reduced (Fig. 14). The 
electroactive complex [Ru(NH3)6]3+, which is capable 
of binding to negatively charged DNA chains due to 
electrostatic interactions, is used for detection [49]. 
The method allows to quantitatively detect telomer-
ase activity in cell line extracts; however, it has not 
been tested on tumor tissue extracts yet. The sensitiv-
ity threshold of this method is the 10-cell extract of 
the telomerase-positive cell line.
Telomerase activity detection using optical biosen-
sors
The principle of this method is to a certain extent simi-
lar to that of SPR. The method is based on the fact that 
upon binding of a target, the refraction index on the 
sensor’s surface changes in proportion to the amount 
of bound targets. A cassette consisting of three oligo-
nucleotides helps to avoid steric impediments. Phos-
phate groups covalently interact with the surface via 
the 5’-end of an oligonucleotide. Then, an oligonucle-
otide containing a short noncomplementary region on 
its 3’-end complementarily binds to the immobilized 
DNA. The prominent 3’-end of the DNA is modified 
with phosphorothioate, which enhances the affinity of 
telomerase-primer binding by a factor of 10 [50]. After 
treatment with a telomerase-containing extract, the 
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enzyme is removed from the sensor’s surface by protei-
nase K in the presence of dNTP (Fig. 15A).
Telomerase activity was assessed in this case by the 
sensogram of the surface charge (ng/mm2, determined 
by the change in the refraction index) (Fig. 15B). The 
method allows to quantitatively detect the telomerase 
activity in cell line extracts; however, it cannot be used 
for tumor tissue extracts, since its sensitivity thresh-
old is the 105-cell extract of the telomerase-positive 
cell line. In addition, phosphorothioate-modified oli-
gonucleotides and a special optosensor are used in this 
method.
The system of telomerase activity detection based on 
quantum dots
A quantum dot is a conductor or semiconductor frag-
ment that is limited along all three spacial dimensions 
and contains conductivity electrons. The dot has to be 
quite small in order to produce considerable quantum 
effects. This can be achieved if the kinetic energy of an 
electron E = ћ2/md (d is the characteristic dimension 
of a dot, m is the effective mass of an electron on the 
dot) conditioned by the uncertainty of its momentum is 
considerably higher than that of all other energy scales, 
primarily, higher than the temperature expressed in 
energy units. Any appreciably small piece of the metal 
or semiconductor can serve as a quantum dot. In this 
microcrystal, an electron feels as if in a three-dimen-
sional potential well; it has many bound energy levels 
with a characteristic distance between them (the ac-
curate expression for the energy levels depends on the 
shape of a dot). Like upon transition between the en-
ergy levels of an atom, a photon can be emitted upon 
transition between the energy levels of a quantum dot. 
Unlike in atoms, the transition frequencies can be eas-
ily controlled by varying the crystal’s dimensions.
A telomere-imitating oligonucleotide modified at its 
end with the thio group is attached to a nanoparticle 
(quantum dot). This quantum dot is capable of fluoresc-
ing by absorbing a quantum with a wavelength of λ1 
(400 nm) and emitting a quantum with a wavelength of 
λ1’ (560 nm). If a modified fluorescent oligonucleotide 
TR-dUTP (dUTP labeled with Texas Red) is incorpo-
rated into DNA upon telomerase-elongation of an oligo-
nucleotide attached to a quantum dot, a fluorescence en-
ergy transfer occurs (Fig. 16A), which is accompanied by 
a decrease in emission with a wavelength of λ1’ and the 
beginning of emission with a wavelength of λ2 (610 nm) 
(Fig. 16B). The method allows for a quantitative assess-
ment of the telomerase activity. The sensitivity thresh-
old is approximately 10,000 HeLa cells [51], which is not 
enough for an analysis of clinical materials.
Instead of incorporating TR-dUTP, it is possible 
to use the ability of telomeric repeats to fold into G-
quadruplexes and bind hemin. In this case, an energy 
transfer takes place between a quantum dot and the 
G-quadruplex–hemin complex with corresponding 
fluorescence quenching. The sensitivity of this method 
is 270 T293 cells [52].
Telomerase activity detection using an on-chip na-
nowire sensor
A sensor chip is a transistor comprising antibody-coat-
ed silicon nanowires with aldehydes groups on their 
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surface, to which monoclonal antibodies can be linked. 
The conductivity of the antibody-coated nanowire var-
ies depending upon the binding of antigens, which is 
detected.
When using a sensor chip to determine telomerase 
activity, the transistor nanowire is modified by tel-
omere-imitating oligonucleotides instead of antibod-
ies. After the introduction of telomerase and dNTP, the 
oligonucleotides bound on the surface elongate, which 
results in change in the conductivity of the transistor to 
which the oligonucleotides are bound [53]. The sensitiv-
ity of this method is 100 HeLa cells.
A similar method is based on using an ion-selective 
field-effect transistor. In the presence of certain chemi-
cal agents, a potential emerges on the shutter of these 
transistors. It opens the conductivity channel of the 
transistor; i.e., current starts flowing through it. The 
current’s intensity is proportional to the concentration 
of the desired component. The Al 2O3-shutter of the 
transistor is modified with a telomerase substrate. As a 
primer is elongated by telomerase, the potential on the 
shutter also changes. The method allows to determine 
telomerase activity in cell line extracts (this method has 
not been tested on clinical materials). Its sensitivity is 65 
T293 cells [54]. The major advantage of the method is 
that a large number of different analyses of one speci-
men can be carried out on a single chip, which can be a 
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set of sensors with respect to various markers. Moreo-
ver, the stages of telomerase binding and dissociation 
can be observed.
Bioluminescence method to determine telomerase ac-
tivity 
Determination of telomerase activity using the biolu-
minescence method is based on the fact that the telom-
erase-catalyzed elongation of the telomere-imitating 
oligonucleotide is accompanied by the cleavage of py-
rophosphate; its amount is determined luminometri-
cally. In the presence of adenosine-5’-phosphosulfate, 
ATP-sulfurylase converts pyrophosphate into ATP; 
its content is determined using the luciferin/luciferase 
method. According to [55], the sensitivity and specifi-
city of the method is comparable with the sensitivity 
of TRAP-ELISA. This method allows quantitative de-
termination of the telomerase activity in cell line and 
tissue extracts (having been tested on lung tumors). 
The advantage of the method is the linear dependence 
of the signal on the amount of telomerase-synthesized 
DNA, combined with high efficiency.
Electrochemiluminescence method to determine tel-
omerase activity
Telomerase activity can also be determined by elec-
trochemiluminescence (luminescence upon electroly-
sis). In this method, the 5’-biotin-conjugated primer is 
elongated by telomerase followed by incubation with 
a suspension of magnetic beads modified with avidin. 
The DNA immobilized on magnetic beads is hybridized 
with an electrochemiluminescence sample (modified 
with a ruthenium-bis(2,2’-bipyridine)(2,2’-bipyridine-
4,4’-bicarbonate)-N-hydroxysuccinimide ester oligonu-
cleotide that is covalently bound to a gold nanoparticle). 
These ternary complexes (magnetic bead–telomeric 
sample–electroluminescence sample) are washed and 
injected into a reaction cuvette in which they are mag-
netized to the working electrode and begin to lumi-
nesce under voltage (Fig. 17). This method allows for 
the quantitative determination of telomerase activity 
in samples that contain at least 500 HeLa cells [56]. It 
provides an appreciably high signal/noise ratio due to 
the stage of magnetic bead extraction; however, it has 
not been tested on clinical materials.
Telomerase activity detection by FRET and total inter-
nal reflection fluorescence microscopy
The FRET-based method is intended to distinguish the 
single-letter synthesis (a nonprocessive method of syn-
thesis) and the beginning of synthesis of the second DNA 
repeat (a conditionally processive method of synthesis) 
by individual complexes of Tetrahymena thermophila 
telomerase. FRET was determined using the total inter-
nal reflection fluorescence microscopy that is based on 
the phenomenon of reflection of electromagnetic waves 
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from the interface of two transparent media. The trans-
parent media emerge under the condition that a wave 
comes from the medium with a higher refraction index, 
at an angle that exceeds the angle of total reflection. The 
intensity of the radiation penetrating into the second 
medium decreases in accordance with the exponential 
law, which allows to reveal the fluorescent objects that 
are excited by this radiation within an ~100-nm thick 
boundary layer with a resolution of up to 10 nm.
Biotin-conjugated primers (TG)8T2G4T2 were bound 
on streptavidin-coated quartz slides and treated with a 
telomerase-containing extract in the presence of dGTP 
and ddTTP; the latter ceasing the synthesis at the sec-
ond repeat. As a result, detectable products of two types 
were formed. The slides with the reaction products were 
treated with a Cy3-labeled oligonucleotide (Cy3-(CA)8) 
in order to stain each primer bound to the slide with Cy3 
because of complementary interaction with a nontelom-
eric region of the oligonucleotide (TG)8. Then, the system 
was treated with a Cy5-labeled detecting oligonucleotide 
(Cy5-C2A2C3), which was complementary to the telom-
eric sequence. This nucleotide can be more effectively 
bound with the longer telomerase product. The FRET 
signal is recorded between Cy3 and Cy5 [57] (Fig. 18). 
The method allows to identify individual signals from 
the elongation of the primer by telomerase.
In order to verify and normalize the system, primers 
of three types labeled with Alexa Fluor-488 were used: 
those corresponding to the sites without synthesis; to 
single-letter synthesis; and to the synthesis of the second 
repeat ((TG)8T2G4T2, (TG)8T2G4T2G, (TG)8T2G4T2G4T) 
with 5’-end biotin, which were bound with streptavidin-
coated quartz slides. Fluorophore Alexa Fluor-488 makes 
it possible to determine the density and localization of 
the primers bound to the slide [57].
The determination of telomerase activity using FRET 
and total internal reflection fluorescence microscopy 
allows to detect the elongation of individual primers 
by telomerase and can be combined with FRET-based 
methods of investigation of the telomerase structure. 
This method can be used to determine only the first 1.5 
telomerase-synthesized repeats; i.e., it does not reveal 
total telomerase activity. The method has been tested 
only on T. thermophila telomerase and has been aimed 
only at solving research problems so far.
DETERMINATION OF TELOMERASE ACTIVITY 
BY ELISA SIGNAL AMPLIFICATION
Determination of telomerase activity using digoxigenin-
labeled oligonucleotides complementary to telomeres
The determination of telomerase-synthesized DNA by 
ELISA is appealing, since it is an isotope-free method. 
This method is based on hybridization of telomerase-
synthesized DNA with a digoxigenin-labeled oligonu-
cleotide and determination of the resulting complex 
by ELISA, using a dioxigenin antibody–alkaline phos-
phatase conjugate (Fig. 8). The sensitivity threshold of 
the method is 10 amol of the product, which is typi-
cal for digoxigenin systems. When using T293 cell ex-
tracts, the sensitivity level was 37,500 cells [58], which 
is insufficient for the analysis of clinical materials. The 
method for determining telomerase-synthesized DNA 
by ELISA is far from being the most sensitive; how-
ever, it has been completely automated and optimized 
for the search for telomerase inhibitors.
Electrochemical determination of telomerase activity 
using avidin  –alkaline phosphatase conjugates
This method is based on ELISA signal amplification 
with electrochemical detection. A thiolized oligonu-
cleotide substrate, which is covalently attached to a 
gold electrode, is elongated by telomerase in the pres-
ence of NTP. ELISA is then carried out (similar to the 
method in which a quartz crystal microbalance is ap-
plied), yielding an insoluble product on the electrode’s 
surface, which is detected electrochemically (Fig. 12). 
Chronopotentiometry (the method based on measuring 
the variation of the electrode potential Е in time under 
a controlled (constant) value of the electrolysis cur-
rent) is used for the detection. The larger the deposit 
No FRET 
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AACCCCAAC
Fig. 18. Telomerase activity detection using FRET and total 
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i
z
e
 
a
n
d
 
a
m
o
u
n
t
 
c
a
n
 
b
e
 
e
s
t
i
m
a
t
e
d
.
L
o
w
 
s
e
n
s
i
t
i
v
i
t
y
,
 
t
h
e
 
n
e
c
e
s
s
i
t
y
 
o
f
 
w
o
r
k
i
n
g
 
w
i
t
h
 
l
a
r
g
e
 
a
m
o
u
n
t
s
 
o
f
 
a
 
r
a
d
i
o
a
c
t
i
v
e
 
l
a
b
e
l
,
 
l
o
n
g
-
t
e
r
m
 
e
x
p
o
s
i
t
i
o
n
.
[
4
3
]
D
e
t
e
r
m
i
n
a
t
i
o
n
 
o
f
 
t
e
l
o
m
e
r
a
s
e
-
s
y
n
t
h
e
s
i
z
e
d
 
D
N
A
 
b
y
 
t
h
e
 
c
h
a
n
g
e
s
 
i
n
 
s
u
r
f
a
c
e
 
p
l
a
s
m
o
n
 
r
e
s
o
n
a
n
c
e
2
0
–
1
0
0
T
h
e
 
a
b
s
e
n
c
e
 
o
f
 
a
r
t
i
f
a
c
t
s
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
P
C
R
.
 
N
o
 
r
a
d
i
o
a
c
-
t
i
v
e
 
l
a
b
e
l
 
a
n
d
 
P
A
A
G
.
 
I
n
f
o
r
m
a
t
i
o
n
 
o
n
 
t
h
e
 
r
e
a
c
t
i
o
n
’
s
 
k
i
n
e
t
-
i
c
s
.
 
T
h
e
 
p
o
s
s
i
b
i
l
i
t
y
 
o
f
 
s
i
g
n
a
l
 
d
e
t
e
c
t
i
o
n
 
a
g
a
i
n
s
t
 
1
,
0
0
0
-
f
o
l
d
 
e
x
c
e
s
s
 
o
f
 
t
e
l
o
m
e
r
a
s
e
-
n
e
g
a
t
i
v
e
 
c
e
l
l
s
.
 
T
e
l
o
m
e
r
a
s
e
 
b
i
n
d
i
n
g
 
a
n
d
 
d
i
s
s
o
c
i
a
t
i
o
n
 
c
a
n
 
b
e
 
o
b
s
e
r
v
e
d
.
T
h
e
 
B
I
A
C
O
R
E
 
s
y
s
t
e
m
 
a
n
d
 
b
i
o
t
i
n
-
c
o
n
j
u
g
a
t
e
d
 
p
r
i
m
e
r
s
 
a
r
e
 
r
e
q
u
i
r
e
d
.
[
4
4
,
 
5
4
]
U
s
i
n
g
 
o
l
i
g
o
-
m
o
d
i
f
i
e
d
 
m
a
g
n
e
t
i
c
 
p
a
r
t
i
c
l
e
s
 
a
n
d
 
N
M
R
1
0
T
h
e
 
a
b
s
e
n
c
e
 
o
f
 
a
r
t
i
f
a
c
t
s
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
P
C
R
.
 
N
o
 
r
a
d
i
o
a
c
-
t
i
v
e
 
l
a
b
e
l
 
a
n
d
 
P
A
A
G
.
A
 
v
e
r
y
 
h
i
g
h
 
p
e
r
f
o
r
m
a
n
c
e
 
m
i
c
r
o
p
l
a
t
e
 
f
o
r
m
a
t
.
A
 
N
M
R
 
s
p
e
c
t
r
o
m
e
t
e
r
 
a
n
d
 
a
 
s
a
m
p
l
e
 
o
f
 
n
a
n
o
p
a
r
-
t
i
c
l
e
s
 
c
o
v
a
l
e
n
t
l
y
 
b
o
u
n
d
 
t
o
 
o
l
i
g
o
n
u
c
l
e
o
t
i
d
e
s
 
a
r
e
 
r
e
q
u
i
r
e
d
.
[
4
6
]
U
s
i
n
g
 
t
h
e
 
q
u
a
r
t
z
 
c
r
y
s
t
a
l
 
m
i
c
r
o
-
b
a
l
a
n
c
e
 
t
e
c
h
n
i
q
u
e
3
3
0
0
T
h
e
 
a
b
s
e
n
c
e
 
o
f
 
a
r
t
i
f
a
c
t
s
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
P
C
R
.
 
H
i
g
h
 
s
e
n
s
i
-
t
i
v
i
t
y
.
 
R
a
p
i
d
 
p
r
o
c
e
d
u
r
e
.
A
 
f
r
e
q
u
e
n
c
y
 
a
n
a
l
y
z
e
r
 
a
n
d
 
a
 
A
u
-
q
u
a
r
t
z
 
c
r
y
s
t
a
l
 
a
r
e
 
r
e
q
u
i
r
e
d
.
 
I
d
e
n
t
i
f
i
c
a
t
i
o
n
 
o
f
 
a
r
t
i
f
a
c
t
 
s
i
g
n
a
l
s
 
(
i
n
 
c
a
s
e
 
o
f
 
e
m
e
r
g
e
n
c
e
)
 
i
s
 
d
i
f
f
i
c
u
l
t
.
[
4
7
]
E
l
e
c
t
r
o
c
h
e
m
i
c
a
l
l
y
,
 
u
s
i
n
g
 
f
e
r
-
r
o
c
e
n
y
l
 
n
a
p
h
t
h
a
l
e
n
e
 
d
i
i
m
i
d
e
1
0
0
–
1
0
0
0
T
h
e
 
a
b
s
e
n
c
e
 
o
f
 
a
r
t
i
f
a
c
t
s
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
P
C
R
.
 
H
i
g
h
 
s
e
n
s
i
-
t
i
v
i
t
y
.
 
R
a
p
i
d
 
p
r
o
c
e
d
u
r
e
.
T
h
e
 
n
u
m
b
e
r
 
o
f
 
s
t
r
u
c
t
u
r
e
s
 
f
o
l
d
e
d
 
i
n
t
o
 
t
h
e
 
q
u
a
d
-
r
u
p
l
e
x
 
i
s
 
a
s
s
e
s
s
e
d
,
 
w
h
i
c
h
 
d
e
p
e
n
d
s
 
n
o
t
 
o
n
l
y
 
o
n
 
t
h
e
 
t
o
t
a
l
 
n
u
m
b
e
r
 
o
f
 
r
e
p
e
a
t
s
,
 
b
u
t
 
a
l
s
o
 
i
s
 
u
n
p
r
e
d
i
c
t
a
b
l
y
 
d
e
p
e
n
d
e
n
t
 
o
n
 
t
h
e
 
l
e
n
g
t
h
 
a
n
d
 
p
o
s
i
t
i
o
n
 
o
f
 
i
n
d
i
v
i
d
u
a
l
 
D
N
A
 
f
r
a
g
m
e
n
t
s
.
[
4
8
]
U
s
i
n
g
 
a
 
b
i
o
b
a
r
c
o
d
e
1
0
O
n
e
 
o
f
 
t
h
e
 
m
o
s
t
 
s
e
n
s
i
t
i
v
e
 
m
e
t
h
o
d
s
 
t
o
d
a
y
 
f
o
r
 
d
i
r
e
c
t
 
t
e
l
o
m
e
r
a
s
e
 
a
c
t
i
v
i
t
y
 
d
e
t
e
c
t
i
o
n
 
w
i
t
h
o
u
t
 
a
m
p
l
i
f
i
c
a
t
i
o
n
 
o
f
 
t
h
e
 
t
e
l
o
m
e
r
a
s
e
-
s
y
n
t
h
e
s
i
z
e
d
 
D
N
A
A
 
m
o
d
i
f
i
e
d
 
e
l
e
c
t
r
o
d
e
 
a
n
d
 
n
a
n
o
p
a
r
t
i
c
l
e
s
 
c
o
a
t
e
d
 
w
i
t
h
 
o
l
i
g
o
n
u
c
l
e
o
t
i
d
e
s
 
o
f
 
t
w
o
 
t
y
p
e
s
 
a
r
e
 
r
e
q
u
i
r
e
d
.
[
4
9
]
U
s
i
n
g
 
o
p
t
i
c
a
l
 
b
i
o
s
e
n
s
o
r
s
1
0
5
N
o
 
r
a
d
i
o
a
c
t
i
v
i
t
y
,
 
n
o
 
P
A
A
G
,
 
n
o
 
P
C
R
.
P
h
o
s
p
h
o
r
o
t
h
i
o
a
t
e
-
m
o
d
i
f
i
e
d
 
o
l
i
g
o
n
u
c
l
e
o
t
i
d
e
s
 
a
n
d
 
a
 
s
p
e
c
i
a
l
 
o
p
t
o
s
e
n
s
o
r
 
a
r
e
 
r
e
q
u
i
r
e
d
.
 
T
h
e
 
s
e
n
s
i
t
i
v
i
t
y
 
i
s
 
i
n
s
u
f
f
i
c
i
e
n
t
 
f
o
r
 
c
l
i
n
i
c
a
l
 
m
a
t
e
r
i
a
l
s
.
[
5
0
]
B
a
s
e
d
 
o
n
 
q
u
a
n
t
u
m
 
d
o
t
s
1
0
,
0
0
0
/
2
7
0
N
o
 
r
a
d
i
o
a
c
t
i
v
i
t
y
,
 
n
o
 
P
A
A
G
,
 
n
o
 
P
C
R
.
O
l
i
g
o
n
u
c
l
e
o
t
i
d
e
s
 
c
o
v
a
l
e
n
t
l
y
 
b
o
u
n
d
 
t
o
 
q
u
a
n
t
u
m
 
d
o
t
s
 
a
r
e
 
r
e
q
u
i
r
e
d
.
 
T
h
e
 
s
e
n
s
i
t
i
v
i
t
y
 
i
s
 
i
n
s
u
f
f
i
c
i
e
n
t
 
f
o
r
 
c
l
i
n
i
c
a
l
 
m
a
t
e
r
i
a
l
s
.
[
5
1
]
U
s
i
n
g
 
a
n
 
o
n
-
c
h
i
p
 
n
a
n
o
w
i
r
e
 
s
e
n
s
o
r
1
0
0
I
t
 
i
s
 
p
o
s
s
i
b
l
e
 
t
o
 
c
a
r
r
y
 
o
u
t
 
a
 
l
a
r
g
e
 
n
u
m
b
e
r
 
o
f
 
d
i
f
f
e
r
e
n
t
 
a
n
a
l
y
s
e
s
 
o
f
 
o
n
e
 
s
p
e
c
i
m
e
n
 
o
n
 
a
 
s
i
n
g
l
e
 
c
h
i
p
.
 
T
e
l
o
m
e
r
a
s
e
 
b
i
n
d
i
n
g
 
a
n
d
 
d
i
s
s
o
c
i
a
t
i
o
n
 
c
a
n
 
b
e
 
o
b
s
e
r
v
e
d
.
A
 
t
r
a
n
s
i
s
t
o
r
 
c
h
i
p
 
a
n
d
 
t
h
e
 
e
q
u
i
p
m
e
n
t
 
t
o
 
a
n
a
l
y
z
e
 
i
t
 
a
r
e
 
r
e
q
u
i
r
e
d
.
[
5
3
]
B
i
o
l
u
m
i
n
e
s
c
e
n
t
 
m
e
t
h
o
d
5
L
i
n
e
a
r
 
d
e
p
e
n
d
e
n
c
e
 
o
f
 
t
h
e
 
s
i
g
n
a
l
 
o
n
 
t
h
e
 
a
m
o
u
n
t
 
o
f
 
t
h
e
 
t
e
l
o
m
e
r
a
s
e
-
s
y
n
t
h
e
s
i
z
e
d
 
D
N
A
.
 
N
o
 
r
a
d
i
o
a
c
t
i
v
i
t
y
,
 
n
o
 
P
A
A
G
,
 
n
o
 
P
C
R
.
 
H
i
g
h
-
e
f
f
i
c
i
e
n
c
y
 
f
o
r
m
a
t
.
T
h
e
 
l
u
c
i
f
e
r
a
s
e
 
s
y
s
t
e
m
 
f
o
r
 
b
i
o
l
u
m
i
n
e
s
c
e
n
c
e
 
d
e
t
e
c
-
t
i
o
n
 
a
n
d
 
a
 
l
u
m
i
n
o
m
e
t
e
r
 
a
r
e
 
r
e
q
u
i
r
e
d
.
[
5
5
]
E
l
e
c
t
r
o
c
h
e
m
i
l
u
m
i
n
e
s
c
e
n
c
e
 
m
e
t
h
o
d
5
0
0
A
 
h
i
g
h
 
s
i
g
n
a
l
/
n
o
i
s
e
 
r
a
t
i
o
 
d
u
e
 
t
o
 
p
u
r
i
f
i
c
a
t
i
o
n
 
b
y
 
m
o
d
i
f
i
e
d
 
m
a
g
n
e
t
i
c
 
b
e
a
d
 
e
x
t
r
a
c
t
i
o
n
.
 
H
i
g
h
 
s
e
n
s
i
t
i
v
i
t
y
.
I
t
 
i
s
 
d
i
f
f
i
c
u
l
t
 
t
o
 
s
y
n
t
h
e
s
i
z
e
 
a
 
s
a
m
p
l
e
,
 
r
e
q
u
i
r
e
m
e
n
t
s
 
t
o
 
t
h
e
 
e
q
u
i
p
m
e
n
t
.
[
5
6
]
U
s
i
n
g
 
F
R
E
T
 
a
n
d
 
t
o
t
a
l
 
i
n
t
e
r
n
a
l
 
r
e
f
l
e
c
t
i
o
n
 
f
l
u
o
r
e
s
c
e
n
c
e
 
m
i
c
r
o
s
-
c
o
p
y
1
E
x
t
r
e
m
e
l
y
 
h
i
g
h
 
s
e
n
s
i
t
i
v
i
t
y
 
–
 
i
t
 
i
s
 
p
o
s
s
i
b
l
e
 
t
o
 
d
e
t
e
c
t
 
t
h
e
 
e
l
o
n
g
a
t
i
o
n
 
o
f
 
i
n
d
i
v
i
d
u
a
l
 
p
r
i
m
e
r
s
 
b
y
 
t
e
l
o
m
e
r
a
s
e
.
 
P
o
s
s
i
b
i
l
i
t
y
 
o
f
 
c
o
m
b
i
n
i
n
g
 
t
h
i
s
 
m
e
t
h
o
d
 
w
i
t
h
 
F
R
E
T
-
b
a
s
e
d
 
m
e
t
h
o
d
s
 
f
o
r
 
i
n
v
e
s
t
i
g
a
t
i
n
g
 
t
h
e
 
t
e
l
o
m
e
r
a
s
e
 
s
t
r
u
c
t
u
r
e
.
T
h
e
 
m
e
t
h
o
d
 
d
e
t
e
r
m
i
n
e
s
 
o
n
l
y
 
t
h
e
 
f
i
r
s
t
 
1
.
5
 
t
e
l
o
m
e
r
a
s
e
-
s
y
n
t
h
e
s
i
z
e
d
 
r
e
p
e
a
t
s
.
 
I
t
 
w
a
s
 
t
e
s
t
e
d
 
o
n
l
y
 
f
o
r
 
T
e
t
r
a
h
y
m
e
n
a
 
t
h
e
r
m
o
p
h
i
l
a
 
t
e
l
o
m
e
r
a
s
e
.
[
5
7
]
U
s
i
n
g
 
d
i
g
o
x
i
g
e
n
i
n
-
l
a
b
e
l
e
d
 
o
l
i
g
o
n
u
c
l
e
o
t
i
d
e
s
 
c
o
m
p
l
e
m
e
n
t
a
r
y
 
t
o
 
t
e
l
o
m
e
r
e
s
 
(
E
L
I
S
A
)
3
7
,
5
0
0
Q
u
a
n
t
i
t
a
t
i
v
e
 
d
e
t
e
r
m
i
n
a
t
i
o
n
;
 
t
h
e
 
m
e
t
h
o
d
 
h
a
s
 
b
e
e
n
 
a
u
t
o
-
m
a
t
e
d
.
T
h
e
 
s
e
n
s
i
t
i
v
i
t
y
 
i
s
 
i
n
s
u
f
f
i
c
i
e
n
t
 
f
o
r
 
c
l
i
n
i
c
a
l
 
m
a
t
e
r
i
a
l
s
.
[
5
8
]
E
l
e
c
t
r
o
c
h
e
m
i
c
a
l
l
y
,
 
u
s
i
n
g
 
a
v
i
d
i
n
 
–
a
l
k
a
l
i
n
e
 
p
h
o
s
p
h
a
t
a
s
e
 
c
o
n
j
u
g
a
t
e
s
3
,
3
0
0
T
h
e
 
a
b
s
e
n
c
e
 
o
f
 
a
r
t
i
f
a
c
t
s
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
P
C
R
.
 
H
i
g
h
 
s
e
n
s
i
-
t
i
v
i
t
y
.
 
R
a
p
i
d
 
p
r
o
c
e
d
u
r
e
.
A
 
s
p
e
c
i
a
l
l
y
 
p
r
e
p
a
r
e
d
 
e
l
e
c
t
r
o
d
e
 
i
s
 
n
e
e
d
e
d
.
 
I
t
 
i
s
 
d
i
f
-
f
i
c
u
l
t
 
t
o
 
i
d
e
n
t
i
f
y
 
a
r
t
i
f
a
c
t
 
s
i
g
n
a
l
s
 
i
f
 
t
h
e
y
 
e
m
e
r
g
e
.
[
4
7
]
U
s
i
n
g
 
a
 
f
l
u
o
r
i
m
e
t
r
i
c
 
o
p
t
o
s
e
n
s
o
r
1
0
6
–
1
0
7
N
o
 
r
a
d
i
o
a
c
t
i
v
i
t
y
,
 
n
o
 
P
A
A
G
,
 
n
o
 
P
C
R
.
P
h
o
s
p
h
o
t
i
o
a
t
e
-
m
o
d
i
f
i
e
d
 
o
l
i
g
o
n
u
c
l
e
o
t
i
d
e
s
 
a
n
d
 
a
n
 
o
p
t
i
c
 
f
i
b
e
r
 
s
y
s
t
e
m
 
f
o
r
 
f
l
u
o
r
e
s
c
e
n
c
e
 
d
e
t
e
c
t
i
o
n
 
a
r
e
 
r
e
q
u
i
r
e
d
.
 
T
h
e
 
s
e
n
s
i
t
i
v
i
t
y
 
i
s
 
i
n
s
u
f
f
i
c
i
e
n
t
 
f
o
r
 
a
n
a
l
y
z
-
i
n
g
 
c
l
i
n
i
c
a
l
 
m
a
t
e
r
i
a
l
s
.
[
5
9
]REVIEWS
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U
s
i
n
g
 
D
N
A
z
y
m
e
-
l
a
b
e
l
e
d
 
o
l
i
g
o
-
n
u
c
l
e
o
t
i
d
e
s
1
,
0
0
0
N
o
 
r
a
d
i
o
a
c
t
i
v
i
t
y
,
 
n
o
 
P
A
A
G
,
 
n
o
 
P
C
R
.
 
S
i
m
p
l
e
 
p
r
o
c
e
d
u
r
e
 
a
n
d
 
s
h
o
r
t
 
a
n
a
l
y
s
i
s
 
t
i
m
e
.
T
h
e
 
s
p
e
c
i
f
i
c
i
t
y
 
o
f
 
t
h
e
 
m
e
t
h
o
d
 
i
s
 
n
o
t
 
v
e
r
y
 
h
i
g
h
;
 
a
 
b
a
c
k
g
r
o
u
n
d
 
s
i
g
n
a
l
 
i
s
 
p
r
e
s
e
n
t
.
[
6
1
]
O
n
 
t
h
e
 
b
a
s
i
s
 
o
f
 
t
h
e
 
t
e
l
o
m
e
r
a
s
e
 
s
u
b
s
t
r
a
t
e
 
t
h
a
t
 
r
e
f
o
l
d
s
 
i
n
 
D
N
A
z
y
m
e
1
0
,
0
0
0
N
o
 
r
a
d
i
o
a
c
t
i
v
i
t
y
,
 
n
o
 
P
A
A
G
,
 
n
o
 
P
C
R
.
 
A
 
v
e
r
y
 
s
i
m
p
l
e
 
p
r
o
c
e
-
d
u
r
e
 
a
n
d
 
s
h
o
r
t
 
a
n
a
l
y
s
i
s
 
t
i
m
e
.
T
h
e
 
s
e
n
s
i
t
i
v
i
t
y
 
a
n
d
 
s
p
e
c
i
f
i
c
i
t
y
 
o
f
 
t
h
e
 
m
e
t
h
o
d
 
a
r
e
 
n
o
t
 
v
e
r
y
 
h
i
g
h
;
 
a
 
b
a
c
k
g
r
o
u
n
d
 
s
i
g
n
a
l
 
i
s
 
p
r
e
s
e
n
t
.
[
6
0
]
T
R
A
P
1
0
A
m
p
l
i
f
i
c
a
t
e
s
 
o
f
 
t
e
l
o
m
e
r
a
s
e
-
s
y
n
t
h
e
s
i
z
e
d
 
D
N
A
 
c
a
n
 
b
e
 
o
b
s
e
r
v
e
d
.
 
P
A
A
G
 
m
a
k
e
s
 
i
t
 
p
o
s
s
i
b
l
e
 
t
o
 
i
d
e
n
t
i
f
y
 
s
o
m
e
 
P
C
R
 
a
r
t
i
f
a
c
t
s
.
 
H
i
g
h
 
s
p
e
c
i
f
i
c
i
t
y
.
W
o
r
k
i
n
g
 
w
i
t
h
 
t
h
e
 
r
a
d
i
o
a
c
t
i
v
e
 
l
a
b
e
l
,
 
n
e
c
e
s
s
i
t
y
 
o
f
 
u
s
i
n
g
 
P
A
A
G
.
 
P
C
R
 
a
r
t
i
f
a
c
t
s
 
a
r
e
 
p
o
s
s
i
b
l
e
.
[
1
1
]
T
R
A
P
 
f
r
o
m
 
a
 
s
i
n
g
l
e
 
c
e
l
l
1
H
i
g
h
 
s
e
n
s
i
t
i
v
i
t
y
.
 
P
A
A
G
 
m
a
k
e
s
 
i
t
 
p
o
s
s
i
b
l
e
 
t
o
 
i
d
e
n
t
i
f
y
 
s
o
m
e
 
P
C
R
 
a
r
t
i
f
a
c
t
s
 
a
n
d
 
q
u
a
l
i
t
a
t
i
v
e
l
y
 
j
u
d
g
e
 
t
h
e
 
p
r
o
c
e
s
s
i
v
i
t
y
.
W
o
r
k
i
n
g
 
w
i
t
h
 
t
h
e
 
r
a
d
i
o
a
c
t
i
v
e
 
l
a
b
e
l
,
 
w
o
r
k
i
n
g
 
w
i
t
h
 
i
n
d
i
v
i
d
u
a
l
 
c
e
l
l
s
,
 
n
e
c
e
s
s
i
t
y
 
o
f
 
u
s
i
n
g
 
P
A
A
G
.
 
P
C
R
 
a
r
t
i
f
a
c
t
s
 
a
r
e
 
p
o
s
s
i
b
l
e
.
[
1
3
]
T
R
A
P
 
w
i
t
h
 
f
l
u
o
r
e
s
c
e
n
t
 
p
r
i
m
e
r
s
1
0
0
N
o
 
r
a
d
i
o
a
c
t
i
v
e
 
l
a
b
e
l
i
n
g
.
 
P
A
A
G
 
m
a
k
e
s
 
i
t
 
p
o
s
s
i
b
l
e
 
t
o
 
i
d
e
n
t
i
f
y
 
s
o
m
e
 
P
C
R
 
a
r
t
i
f
a
c
t
s
 
a
n
d
 
q
u
a
l
i
t
a
t
i
v
e
l
y
 
j
u
d
g
e
 
t
h
e
 
p
r
o
c
e
s
s
i
v
i
t
y
.
N
e
c
e
s
s
i
t
y
 
o
f
 
f
l
u
o
r
e
s
c
e
n
t
l
y
 
l
a
b
e
l
e
d
 
p
r
i
m
e
r
s
,
 
n
e
c
e
s
-
s
i
t
y
 
o
f
 
u
s
i
n
g
 
P
A
A
G
.
 
P
C
R
 
a
r
t
i
f
a
c
t
s
 
a
r
e
 
p
o
s
s
i
b
l
e
.
[
2
0
]
T
R
A
P
 
w
i
t
h
 
f
l
u
o
r
e
s
c
e
n
t
 
s
t
a
i
n
i
n
g
 
o
f
 
D
N
A
 
i
n
 
g
e
l
1
0
N
o
 
r
a
d
i
o
a
c
t
i
v
e
 
l
a
b
e
l
i
n
g
.
 
P
A
A
G
 
m
a
k
e
s
 
i
t
 
p
o
s
s
i
b
l
e
 
t
o
 
i
d
e
n
t
i
f
y
 
s
o
m
e
 
P
C
R
 
a
r
t
i
f
a
c
t
s
 
a
n
d
 
q
u
a
l
i
t
a
t
i
v
e
l
y
 
j
u
d
g
e
 
t
h
e
 
p
r
o
c
e
s
s
i
v
i
t
y
.
N
e
c
e
s
s
i
t
y
 
o
f
 
u
s
i
n
g
 
P
A
A
G
.
 
P
C
R
 
a
r
t
i
f
a
c
t
s
 
a
r
e
 
p
o
s
s
i
b
l
e
.
 
M
o
s
t
 
i
n
t
e
r
c
a
l
a
t
i
n
g
 
f
l
u
o
r
e
s
c
e
n
t
 
d
y
e
s
 
a
r
e
 
m
u
t
a
g
e
n
i
c
.
[
1
6
,
 
1
8
]
T
R
A
P
 
w
i
t
h
 
D
N
A
 
s
t
a
i
n
i
n
g
 
w
i
t
h
 
s
i
l
v
e
r
 
n
i
t
r
i
t
e
 
i
n
 
g
e
l
1
0
N
o
 
r
a
d
i
o
a
c
t
i
v
e
 
l
a
b
e
l
i
n
g
.
 
P
A
A
G
 
m
a
k
e
s
 
i
t
 
p
o
s
s
i
b
l
e
 
t
o
 
i
d
e
n
t
i
f
y
 
s
o
m
e
 
P
C
R
 
a
r
t
i
f
a
c
t
s
 
a
n
d
 
q
u
a
l
i
t
a
t
i
v
e
l
y
 
j
u
d
g
e
 
t
h
e
 
p
r
o
c
e
s
s
i
v
i
t
y
.
N
e
c
e
s
s
i
t
y
 
o
f
 
u
s
i
n
g
 
P
A
A
G
.
P
o
s
s
i
b
i
l
i
t
y
 
o
f
 
P
C
R
 
a
r
t
i
f
a
c
t
s
.
 
H
i
g
h
 
l
a
b
o
r
 
i
n
p
u
t
.
[
1
7
]
T
R
A
P
 
w
i
t
h
 
a
n
a
l
y
z
i
n
g
 
b
y
 
s
c
i
n
t
i
l
-
l
a
t
i
o
n
 
p
r
o
x
i
m
i
t
y
 
a
s
s
a
y
1
0
N
o
 
r
a
d
i
o
a
c
t
i
v
i
t
y
,
 
n
o
 
P
A
A
G
.
 
H
i
g
h
l
y
 
e
f
f
i
c
i
e
n
t
 
m
i
c
r
o
p
l
a
t
e
 
f
o
r
m
a
t
.
 
S
i
m
p
l
e
 
e
s
t
i
m
a
t
i
o
n
 
o
f
 
t
h
e
 
a
m
o
u
n
t
s
.
N
e
c
e
s
s
i
t
y
 
o
f
 
u
s
i
n
g
 
[
3
H
]
T
T
Р
 
a
n
d
 
b
i
o
t
i
n
-
c
o
n
j
u
g
a
t
e
d
 
p
r
i
m
e
r
s
.
 
W
o
r
k
i
n
g
 
w
i
t
h
 
t
r
i
t
i
u
m
.
 
P
C
R
 
a
r
t
i
f
a
c
t
s
 
a
r
e
 
p
o
s
s
i
b
l
e
.
[
2
7
]
T
R
A
P
 
w
i
t
h
 
d
e
t
e
c
t
i
o
n
 
b
y
 
“
h
y
b
r
i
d
i
z
a
t
i
o
n
 
p
r
o
t
e
c
t
i
o
n
”
1
0
N
o
 
r
a
d
i
o
a
c
t
i
v
i
t
y
,
 
n
o
 
P
A
A
G
.
 
H
i
g
h
l
y
 
e
f
f
i
c
i
e
n
t
 
m
i
c
r
o
p
l
a
t
e
 
f
o
r
m
a
t
.
 
S
i
m
p
l
e
 
e
s
t
i
m
a
t
i
o
n
 
o
f
 
t
h
e
 
a
m
o
u
n
t
s
.
A
c
r
i
d
i
n
e
-
l
a
b
e
l
e
d
 
s
a
m
p
l
e
s
 
a
r
e
 
r
e
q
u
i
r
e
d
.
 
P
C
R
 
a
r
t
i
f
a
c
t
s
 
a
r
e
 
p
o
s
s
i
b
l
e
.
[
2
8
]
T
R
A
P
 
w
i
t
h
 
a
m
p
l
i
f
l
u
o
r
e
 
p
r
i
m
e
r
s
1
0
-
5
0
N
o
 
r
a
d
i
o
a
c
t
i
v
i
t
y
,
 
n
o
 
P
A
A
G
.
 
H
i
g
h
l
y
 
e
f
f
i
c
i
e
n
t
 
m
i
c
r
o
p
l
a
t
e
 
f
o
r
m
a
t
.
 
Q
u
a
n
t
i
t
a
t
i
v
e
 
a
s
s
e
s
s
m
e
n
t
.
 
D
i
f
f
e
r
e
n
t
 
l
a
b
e
l
i
n
g
 
o
f
 
a
m
p
l
i
f
i
c
a
t
e
s
 
b
y
 
t
h
e
 
t
e
l
o
m
e
r
a
s
e
-
s
y
n
t
h
e
s
i
z
e
d
 
D
N
A
 
a
n
d
 
P
C
R
 
c
o
n
t
r
o
l
.
P
C
R
 
a
r
t
i
f
a
c
t
s
 
a
r
e
 
p
o
s
s
i
b
l
e
.
 
A
m
p
l
i
f
l
u
o
r
e
s
 
a
r
e
 
r
e
q
u
i
r
e
d
.
[
2
2
]
T
R
A
P
 
c
o
m
b
i
n
e
d
 
w
i
t
h
 
E
L
I
S
A
1
0
N
o
 
r
a
d
i
o
a
c
t
i
v
i
t
y
,
 
n
o
 
P
A
A
G
.
 
H
i
g
h
l
y
 
e
f
f
i
c
i
e
n
t
 
m
i
c
r
o
p
l
a
t
e
 
f
o
r
m
a
t
.
P
C
R
 
a
n
d
 
E
L
I
S
A
 
a
r
t
i
f
a
c
t
s
 
a
r
e
 
p
o
s
s
i
b
l
e
.
[
2
9
]
T
R
A
P
 
w
i
t
h
 
p
r
i
m
e
r
s
 
w
i
t
h
 
f
l
u
o
r
e
s
c
e
n
c
e
 
r
e
s
o
n
a
n
c
e
 
e
n
e
r
g
y
 
t
r
a
n
s
f
e
r
 
(
F
R
E
T
)
1
0
N
o
 
r
a
d
i
o
a
c
t
i
v
i
t
y
,
 
n
o
 
P
A
A
G
.
 
H
i
g
h
l
y
 
e
f
f
i
c
i
e
n
t
 
m
i
c
r
o
p
l
a
t
e
 
f
o
r
m
a
t
.
U
n
e
q
u
a
l
 
c
o
n
s
i
d
e
r
a
t
i
o
n
 
o
f
 
t
h
e
 
f
i
r
s
t
 
a
n
d
 
s
u
b
s
e
q
u
e
n
t
 
r
e
p
e
a
t
s
 
s
y
n
t
h
e
s
i
z
e
d
 
b
y
 
t
e
l
o
m
e
r
a
s
e
 
w
h
e
n
 
c
a
r
r
y
i
n
g
 
o
u
t
 
t
h
e
 
q
u
a
n
t
i
t
a
t
i
v
e
 
a
s
s
e
s
s
m
e
n
t
.
 
P
C
R
 
a
r
t
i
f
a
c
t
s
 
a
r
e
 
p
o
s
s
i
b
l
e
.
 
S
p
e
c
i
a
l
 
f
l
u
o
r
o
p
h
o
r
e
s
 
a
r
e
 
r
e
q
u
i
r
e
d
.
[
2
6
]
T
R
A
P
 
o
n
 
m
i
c
r
o
c
h
i
p
s
1
0
N
o
 
r
a
d
i
o
a
c
t
i
v
i
t
y
,
 
n
o
 
P
A
A
G
.
 
S
m
a
l
l
 
r
e
a
c
t
i
o
n
 
v
o
l
u
m
e
s
.
 
H
i
g
h
l
y
 
e
f
f
i
c
i
e
n
t
 
m
i
c
r
o
p
l
a
t
e
 
f
o
r
m
a
t
.
 
S
i
m
p
l
e
 
e
s
t
i
m
a
t
i
o
n
 
o
f
 
t
h
e
 
a
m
o
u
n
t
s
.
C
h
i
p
s
 
a
n
d
 
a
n
 
i
n
s
t
r
u
m
e
n
t
 
t
o
 
r
e
a
d
 
t
h
e
m
 
a
r
e
 
n
e
c
e
s
-
s
a
r
y
.
[
3
5
]
T
R
A
P
 
w
i
t
h
 
r
e
a
l
-
t
i
m
e
 
P
C
R
5
0
N
o
 
r
a
d
i
o
a
c
t
i
v
i
t
y
,
 
n
o
 
P
A
A
G
.
 
H
i
g
h
l
y
 
e
f
f
i
c
i
e
n
t
 
m
i
c
r
o
p
l
a
t
e
 
f
o
r
m
a
t
.
 
S
i
m
p
l
e
 
e
s
t
i
m
a
t
i
o
n
 
o
f
 
t
h
e
 
a
m
o
u
n
t
s
.
 
D
i
f
f
e
r
e
n
t
 
l
a
b
e
-
l
i
n
g
 
o
f
 
a
m
p
l
i
f
i
c
a
t
e
s
 
o
f
 
t
h
e
 
t
e
l
o
m
e
r
a
s
e
-
s
y
n
t
h
e
s
i
z
e
d
 
D
N
A
 
a
n
d
 
P
C
R
 
c
o
n
t
r
o
l
 
w
i
t
h
 
a
m
p
l
i
f
l
u
o
r
e
s
 
i
s
 
p
o
s
s
i
b
l
e
.
A
n
 
a
m
p
l
i
f
i
e
r
 
f
o
r
 
r
e
a
l
-
t
i
m
e
 
P
C
R
 
i
s
 
r
e
q
u
i
r
e
d
.
 
T
h
e
 
i
d
e
n
t
i
f
i
c
a
t
i
o
n
 
o
f
 
P
C
R
 
a
r
t
i
f
a
c
t
s
 
i
s
 
c
o
m
p
l
i
c
a
t
e
d
.
[
3
2
,
 
3
3
]
I
n
 
s
i
t
u
 
T
R
A
P
1
T
h
e
 
m
e
t
h
o
d
 
p
r
o
v
i
d
e
s
 
i
n
f
o
r
m
a
t
i
o
n
 
o
n
 
t
h
e
 
t
e
l
o
m
e
r
a
s
e
 
a
c
t
i
v
i
t
y
 
i
n
 
i
n
d
i
v
i
d
u
a
l
 
c
e
l
l
s
 
a
n
d
 
s
o
m
e
 
i
n
f
o
r
m
a
t
i
o
n
 
o
n
 
e
n
d
o
-
c
e
l
l
u
l
a
r
 
l
o
c
a
l
i
z
a
t
i
o
n
 
o
f
 
t
h
e
 
a
c
t
i
v
i
t
y
.
A
 
c
o
m
p
l
i
c
a
t
e
d
 
p
r
o
c
e
d
u
r
e
.
 
L
o
w
 
e
f
f
i
c
i
e
n
c
y
.
 
A
 
f
l
u
o
-
r
e
s
c
e
n
c
e
 
m
i
c
r
o
s
c
o
p
e
 
i
s
 
r
e
q
u
i
r
e
d
.
 
T
h
e
 
m
e
t
h
o
d
 
h
a
s
 
b
e
e
n
 
o
p
t
i
m
i
z
e
d
 
o
n
l
y
 
f
o
r
 
a
n
a
l
y
z
i
n
g
 
c
l
i
n
i
c
a
l
 
s
a
m
p
l
e
s
 
a
n
d
 
c
e
l
l
 
l
i
n
e
s
.
[
3
6
]
T
R
A
P
 
w
i
t
h
 
t
r
a
n
s
c
r
i
p
t
i
o
n
a
l
 
a
m
p
l
i
f
i
c
a
t
i
o
n
1
0
I
s
o
t
h
e
r
m
a
l
 
a
m
p
l
i
f
i
c
a
t
i
o
n
,
 
n
o
 
P
C
R
 
a
r
t
i
f
a
c
t
s
,
 
P
A
A
G
-
f
r
e
e
 
d
e
t
e
c
t
i
o
n
,
 
h
i
g
h
l
y
 
e
f
f
i
c
i
e
n
t
 
f
o
r
m
a
t
.
A
c
r
i
d
i
n
e
-
l
a
b
e
l
e
d
 
s
a
m
p
l
e
s
 
a
r
e
 
r
e
q
u
i
r
e
d
.
 
A
r
t
i
f
a
c
t
s
 
o
f
 
t
r
a
n
s
c
r
i
p
t
i
o
n
a
l
 
a
m
p
l
i
f
i
c
a
t
i
o
n
 
a
r
e
 
p
o
s
s
i
b
l
e
.
 
H
i
g
h
e
r
 
r
e
q
u
i
r
e
m
e
n
t
s
 
o
f
 
p
u
r
i
t
y
 
(
a
b
s
e
n
c
e
 
o
f
 
R
N
a
s
e
s
)
 
b
e
c
a
u
s
e
 
o
f
 
t
h
e
 
t
r
a
n
s
c
r
i
p
t
i
o
n
a
l
 
a
m
p
l
i
f
i
c
a
t
i
o
n
.
[
4
2
]
*
 
T
h
e
 
m
i
n
i
m
u
m
 
n
u
m
b
e
r
 
o
f
 
c
e
l
l
s
 
o
f
 
t
e
l
o
m
e
r
a
s
e
-
p
o
s
i
t
i
v
e
 
c
e
l
l
 
l
i
n
e
s
 
f
o
r
 
w
h
i
c
h
 
a
c
t
i
v
i
t
y
 
c
a
n
 
b
e
 
d
e
t
e
c
t
e
d
.
*
*
 
I
n
 
P
A
A
G
-
f
r
e
e
 
m
e
t
h
o
d
s
 
(
w
i
t
h
 
t
h
e
 
e
x
c
e
p
t
i
o
n
 
o
f
 
d
e
t
e
r
m
i
n
a
t
i
o
n
 
o
f
 
t
e
l
o
m
e
r
a
s
e
 
a
c
t
i
v
i
t
y
 
u
s
i
n
g
 
F
R
E
T
 
a
n
d
 
t
o
t
a
l
 
i
n
t
e
r
n
a
l
 
r
e
f
l
e
c
t
i
o
n
 
f
l
u
o
r
e
s
c
e
n
c
e
 
m
i
c
r
o
s
c
o
p
y
)
,
 
p
o
l
y
m
e
r
a
s
e
 
a
c
t
i
v
i
t
y
 
(
b
u
t
 
n
o
t
 
p
r
o
c
e
s
s
i
v
i
t
y
)
 
i
s
 
a
s
s
e
s
s
e
d
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on the electrode’s surface, the stronger the variation of 
the potential. This method allows for the quantitative 
determination of telomerase activity in tissue and cell 
line extracts at a high rate [47]. The sensitivity of this 
method is sufficient for determining telomerase activ-
ity in an extract corresponding to 1,000 HeLa cells.
Determination of telomerase activity using a fluori-
metric optosensor
This optical sensor is based on fluorimetry (in fact, it is 
a fluorimeter with an optical fiber used in the excitation 
and detection systems). The oligonucleotide, the telomer-
ase substrate, is modified at the 3’-end by phosphotioate 
in order to enhance the affinity of the telomere-oligo-
nucleotide binding region of hTERT and, therefore, the 
rate of the telomerase reaction. This primer covalently 
binds to the surface of an optical biosensor; its elonga-
tion by telomerase is traced in real time by incorpora-
tion of dUTP labeled with a isothiocyanate fluorescein 
derivative (FITC), or the elongated chain is determined 
by hybridization of the FITC-labeled complementary 
DNA sample ((CCAATC)4-FITC) (Fig. 19). No PCR am-
plification or additional purification stages are required 
in this method [59]. Furthermore, the efficiency of the 
telomerase function was compared in the presence 
of regular dNTP and in the presence of FITC-labeled 
dUTP. In order to achieve this, telomerase-synthesized 
DNA, in the presence of FITC-labeled dUTP, was la-
beled with a FITC-labeled complementary DNA sample. 
It turned out that telomerase was less efficient in the 
presence of FITC-labeled dUTP [59]. This method al-
lows for the quantitative determination of telomerase 
activity; however, its sensitivity does not exceed 106–107, 
which is insufficient for analyzing clinical materials. In 
addition, this method uses the custom-built system of 
fluorescence detection.
Determination  of  telomerase  activity  using 
DNAzymes
DNAzymes are DNA fragments with enzymatic activ-
ity.
There are several ways in which DNAzymes can be 
used when analyzing telomerase. First, a telomerase 
substrate may have a hairpin at its 5’-end, which re-
folds as the substrate elongates, thus forming a cata-
lytic structure (Fig. 20A). In doing so, one chain of the 
original hairpin forms a duplex with the de novo syn-
thesized telomeric repeats, while the second hairpin 
in the presence of a hemin molecule forms a quadru-
plex with an incorporated hemin molecule with per-
oxidase activity. This complex catalyzes the oxidation 
of 2,2’-azino-bis(3-ethylbenzthiazoline)-6-sulfonic acid 
(ABTS) in the presence of H2O2, which results in the ac-
cumulation of a colored product (Fig. 20). The sensitiv-
ity of this method is approximately 10,000 HeLa cells, 
with a duration of the analysis of approximately 8 min 
[60]. The slow change in coloration of the extract from 
the control cells after the thermal treatment should be 
noted. These authors believe that this is associated with 
the nonspecific hemin sorption on the reaction mixture 
components. This method represents the number of 
elongated substrate molecules; however, it does not 
take into account the length of the chain synthesized 
by telomerase. 
Similarly, a DNAzyme that is covalently linked with 
the antisense oligonucleotide can be used for the tel-
omerase-synthesized DNA [61] (Fig. 20B). It is virtually 
similar to ELISA in which an enzyme has already been 
covalently linked to the probe. The sensitivity of this 
modification is approximately 1,000 HeLa cells upon a 
lower background. The drawbacks of the method in-
clude low sensitivity and specificity, as well as the pres-
ence of a background signal.
CONCLUSIONS
At the time of publication of this article, there were a 
number of methods for the determination of telomerase 
activity in various specimens: extracts of cells, tissues, 
and mixed cell populations. All the aforementioned 
methods can be divided into two groups: those with 
direct detection of telomerase-synthesized DNA and 
those with various amplification schemes; each method 
Primer
+FITC-dUTP
Detection
AUCCCAAUC
Fig. 19. Scheme 
of formation of 
fluorescence-
labeled telomer-
ase-synthesized 
DNA detection 
by a fluorimetric 
optical sensor 
[59].REVIEWS
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Two schemes for 
telomerase activ-
ity detection with 
DNAenzymes 
[60, 61].
has its advantages and drawbacks. A comparison of all 
these methods is provided in Table 2.
After the consideration of all the methods, a number 
of new systems can be singled out which are compa-
rable in terms of sensitivity with the TRAP method, 
the most commonly used method at the moment. They 
do not have artifacts associated with amplification; the 
analysis is carried out at a high rate with high sensitiv-
ity. Meanwhile, they have a number of drawbacks, in-
cluding high requirements to the specific supplies and 
equipment. Therefore, the selection of a technique in 
each particular case can be determined by the avail-
ability of the equipment and reagents. In a number of 
methods, it is difficult to distinguish between the spe-
cific and nonspecific signals. Most methods assess only 
telomerase activity, but not its processivity. They fre-
quently provide no information on the length distribu-
tion of the telomerase-synthesized DNA. Some methods 
are highly specialized; e.g., the method in which telom-
erase-synthesized DNA is determined using dioxigen-
in-labeled oligonucleotides that are complementary to 
telomeres (ELISA) without PCR is far from being the 
most sensitive method; however, it has been completely 
automated and optimized for the search for telomerase 
inhibitors. The determination of telomerase activity by 
FRET and total internal reflection fluorescence micro-
scopy makes it possible to detect the elongation of indi-
vidual primers by telomerase, which can be combined 
with FRET-based methods for investigating the telom-
erase structure; however, it allows detection of only the 
first 1.5 telomerase-synthesized repeats and is intended 
for research purposes.  
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